Pharmacoeconomic considerations in the treatment of multiple sclerosis

Drugs

Volumn 70, Issue 13, 2010, Pages 1677-1691

  Sharac, Jessica ^a   McCrone, Paul ^a   Sabes Figuera, Ramon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cost effectiveness; cost minimisation; cost of illness; cost utility; cyclophosphamide, therapeutic use; glatiramer acetate, therapeutic use; interferon beta 1a, therapeutic use; interferon beta 1b, therapeutic use; mitoxantrone, therapeutic use; multiple sclerosis, treatment; natalizumab, therapeutic use.

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MULTIPLE SCLEROSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW;

ADJUVANTS, IMMUNOLOGIC; COST OF ILLNESS; ECONOMICS, PHARMACEUTICAL; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 77956089192     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11538000-000000000-00000     Document Type: Review

References (58)

1. Battaglia MA, Zagami P, Uccelli MM. A cost evaluation of multiple sclerosis. J Neurovirol 2000; 6 Suppl. 2: S191-3
2. Bryant J, Clegg A, Milne R. Systematic review of immuno-modulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and costi J Neurol Neurosurg Psychiatry 2001; 70 (5): 574-579
3. Clegg A, Bryant J. Immunomodulatory drugs for mul-tiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001; 2 (4): 623-639
4. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77 (8): 918-926 (Pubitemid 44174075)
5. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001; 8 (1): 27-35
6. McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008; 26 (10): 847-860
7. Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 2007; 13 (8): 1054-1064
8. Casado V, Romero L, Gubieras L, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler 2007; 13 (6): 800-804
9. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007; 13 (1): 44-52
10. Taylor B, McDonald E, Fantino B, et al. The cost of mul-tiple sclerosis in Australia. J Clin Neurosci 2007; 14 (6): 532-539
11. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006; 7 Suppl. 2: S45-54
12. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006; 7 Suppl. 2: S34-44
13. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 2006; 7 Suppl. 2: S86-95
14. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 2006; 7 Suppl. 2: S14-23
15. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006; 7 Suppl. 2: S65-74
16. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006; 7 Suppl. 2: S96-104
17. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006; 7 Suppl. 2: S75-85
18. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in the Netherlands. Eur J Health Econ 2006; 7 Suppl. 2: S55-64
19. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006; 7 Suppl. 2: S24-33
20. Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. Direct and indirect costs of multiple sclerosis in Baix Llo-bregat (Catalonia, Spain), according to disability. BMC Health Serv Res 2006; 6: 143
21. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006; 66 (11): 1696-1702 (Pubitemid 43964625)
22. Orlewska E, Mierzejewski P, Zaborski J, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 2005; 12 (1): 31-39
23. Russo P, Capone A, Paolillo A, et al. Cost-analysis of re-lapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Investig 2004; 24 (7): 409-420
24. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249 (2): 152-163
25. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: an observational study in Germany. HEPAC 2001; 2 (2): 60-68
26. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000; 6 (2): 91-98
27. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4 (5): 419-425
28. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis. Part I: cost of illness. Can J Neurol Sci 1998; 25 (1): 23-30
29. Murphy N, Confavreux C, Haas J, et al. Economic evalua-tion of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998; 13 (5 Pt 2): 607-622
30. Henriksson F, Jonsson B. The economic cost of multiple sclerosis in Sweden in Pharmacoeconomics 1998; 13 (5 Pt 2): 597-606
31. Asche CV, Ho E, Chan B, et al. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 1997; 95 (5): 268-274
32. Blumhardt LD, Wood C. The economics of multiple sclerosis: a cost of illness study. Br J Med Econ 1996; 10 (2): 99-118
33. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ 1995; 8 (4): 181-193
34. Bourdette DN, Prochazka AV, Mitchell W, et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. Arch Phys Med Rehabil 1993; 74 (1): 26-31
35. Carton H, Loos R, Pacolet J, et al. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 1998 Apr; 64 (4): 444-450
36. Link B. Understanding labeling effects in the area of mental disorders: an assessment of the effects of expectation of rejection. Am Soc Rev 1987; 52 (1): 96-112
37. Link B. Mental patient status, work, and income: an exam-ination of the effects of a psychiatric label. Am Sociol Rev 1982 Apr; 47 (2): 202-215
38. Brown MG, Murray TJ, Sketris IS, et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates. Int J Technol Assess Health Care 2000; 16 (3): 751-767
39. Parkin D, Jacoby A, McNamee P, et al. Treatment of mul-tiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000; 68 (2): 144-149
40. Forbes RB, Lees A, Waugh N, et al. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999; 319 (7224): 1529-1533
41. Nuijten MJ, Hutton J. Cost-effectiveness analysis of inter-feron beta in multiple sclerosis: a Markov process analysis. Value Health 2002 Jan; 5 (1): 44-54
42. Kobelt G, Jonsson L, Henriksson F, et al. Cost-utility ana-lysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 2000; 16 (3): 768-780
43. Kobelt G, Jonsson L, Miltenburger C, et al. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health Care 2002; 18 (1): 127-138
44. 1b in the treatment of patients with active relap-sing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ 2003; 4 (1): 50-59
45. Phillips CJ, Gilmour L, Gale R, et al. A cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 2001; 4 (1-4): 35-50
46. Lepen C, Coyle P, Vollmer T, et al. Long-term cost effec-tiveness of interferon-beta-1a in the treatment of relapsing-remitting multiple sclerosis: an econometric model. Clin Drug Investig 2003; 23 (9): 571-581
47. Iskedjian M, Walker JH, Gray T, et al. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler 2005 Oct; 11 (5): 542-551
48. Bose U, Ladkani D, Burrell A, et al. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Drug Assess 2002; 5 (1): 67-79
49. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003; 326 (7388): 522-525
50. Touchette DR, Durgin TL, Wanke LA, et al. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther 2003 Feb; 25 (2): 611-634
51. Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004; 7 (5): 554-568
52. Perini P, Calabrese M, Tiberio M, et al. Mitoxantrone ver-sus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol 2006; 253 (8): 1034-1040
53. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007; 13 (3): 245-261
54. Matschay A, Nowakowska E, Hertmanowska H, et al. Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland. Pharmacol Rep 2008; 60 (5): 632-644
55. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharma-coeconomics 2008; 26 (7): 617-627
56. Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008; 14 (5): 679-690
57. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33 (11): 1444-1452
58. Williams A. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (3): 199-208